Description
Recombinant Human PAK3 Protein (His Tag)(Active) | PKSH030366 | Gentaur US, UK & Europe Disrtribition
Synonyms: bPAK;CDKN1A;hPAK3;MRX30;MRX47;OPHN3;PAK3beta
Active Protein: Active protein
Activity: A DNA sequence encoding the human PAK3 isoform 2 (O75914-2) (Met 1-Arg 544) was fused with a polyhistidine tag at the C-terminus.
Protein Construction: A DNA sequence encoding the human PAK3 isoform 2 (O75914-2) (Met 1-Arg 544) was fused with a polyhistidine tag at the C-terminus.
Fusion Tag: C-His
Species: Human
Expressed Host: Baculovirus-Insect Cells
Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C.
Purity: > 80 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Molecular Mass: 62 kDa
Formulation: Supplied as sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% glycerol
Reconstitution: Not Applicable
Background: PAK3 is a member of PAK proteins, a family of serine/threonine p21-activating kinases, serve as effectors of small Rho GTPases Cdc42 and RAC and have been implicated in a wide range of biological activities. There are six mammalian PAKs which can be divided into two groups: group I PAKs (PAK1-3) and group II PAKs (PAK4-6). Although the two PAK groups are architecturally similar there are differences in their mode of regulation suggesting their cellular functions are likely to be different. Group I p21-activated kinases (PAK1/2/3) is demonstrated as ERK3/ERK4 activation loop kinases. It has been shown that group I PAKs phosphorylate ERK3 and ERK4 on Ser-189 and Ser-186, respectively, both in vitro and in vivo, and that expression of activated Rac1 augments this response. Besides regulation enzymatic activation of ERK3/ERK4, PAKs can also play roles in downstream activation of MAP kinase-activated protein kinase 5 (MK5) in vivo. Thus, the group I PAKs act as upstream activators of ERK3 and ERK4 and unravel a novel PAK-ERK3/ERK4-MK5 signaling pathway. In clinical, PAK has been proposed as a potential therapeutic target in schwannomas.
Research Area: N/A
